新股發售 | 和譽：專注腫瘤新藥研發，淡馬錫、貝萊德、奧博資本等入股
和譽生物是一家研發驅動、臨牀階段的生物醫藥公司，專注於當今癌症治療兩大核心領域–小分子腫瘤靶向和腫瘤免疫藥物研發，由徐耀昌博士、喻紅平博士以及陳椎博士於2016年聯合創立。公司主要就治療肝細胞癌(HCC)、尿路上皮癌(UC)及胃癌(GC)開發核心候選產品，目前已建立14種專注於精確腫瘤學和腫瘤免疫治療綜合組成的研發管線，其中5中處於臨牀階段。
核心產品有2款ABSK011及ABSK091，ABSK011被開發用於治療FGF19/FGFR4信號高度活化的晚期肝細胞癌(HCC)。ABSK091用於治療多種實體瘤，包括但不限於尿路上皮癌、胃癌、膽管癌及肺癌。目前都處於早期開發階段，公司已完成ABSK011的Ia期臨牀試驗及ABSK091的I期臨牀試驗。
1、招股信息
(1)簡稱及代碼: 和譽-B，2256.HK
(2)招股日期: 9.30-10.6
上市日期: 10.13
計息日: 6天
(3)發行價格: 12.16-12.46港元
(4)入場費: 25171.12港元，乙頭需認購45萬股（225手），金額約566.3萬港元，若以20倍槓桿，3.5%年化利率計算，乙頭融資利息成本約爲3100港元
(5)發行股數: 1.40736股，90%國際配售，10%公開發售，1手500股
(6)超額配股權: 有，可按發售價發行最多2110.8萬股(佔發售股份的15%)，以補足國配的超額認購
(7)集資金額: 17.113-17.536億港元
(8)市值: 85.42-87.527億港元
(9)PE: 虧損
(10)保薦人: 摩根士丹利、摩根大通
(11)基石: 11名，共認購約9.9億港元股票，佔發售股份的56.63-58.03%，包括禮來亞洲基金、淡馬錫、貝萊德、Janchor、清池資本、奧博資本、Epsomite等，以上所列均爲公司老股東
2、回撥機制
15倍以內，公開比例爲10%，甲乙組分別有3519手
15-50倍，公開比例提升至30%，甲乙組分別有10555手
50-100倍，公開比例提升至40%，甲乙組分別有14074手
100倍或以上，公開比例提升至50%，甲乙組分別有17592萬手
3、IPO前投資者
和譽生物自成立以來已完成了5輪融資，融資總金額累計達2.63億美元，2020年12月最新一輪融資後的估值爲7.23億美元。投資方衆多有23家，包括禮來亞洲基金、國藥資本、建信資本、泰福資本、啓明創投、正心谷資本、中金資本、淡馬錫、GIC、華平投資、凱雷、奧博資本、清池資本等國內外知名機構。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
